Trial results

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

NCT06184568 on ClinicalTrials.gov · last registry update 2026-06-11

Finished 17 September 2025, after enrolling 349 people. Primary outcome, as filed: Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Sponsor type

Industry

Enrollment

349

Started

2024-02-29

Primary completion

2025-09-17 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss

Conditions studied

Type 2 Diabetes · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.